dronabinol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
cannabinoid receptors agonists 4109 1972-08-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tetrahydrocannabinol
  • THC
  • dronabinol
  • marinol
A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.
  • Molecular weight: 314.47
  • Formula: C21H30O2
  • CLOGP: 7.24
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 29.46
  • ALOGS: -5.08
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.91 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 8.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 33 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 31, 1985 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Decreased appetite 74.20 16.22 116 7229 250936 63230741
Dehydration 52.38 16.22 81 7264 173273 63308404
Failure to thrive 50.89 16.22 22 7323 7176 63474501
Nausea 49.49 16.22 212 7133 854259 62627418
Death 39.98 16.22 114 7231 374267 63107410
Vomiting 38.75 16.22 147 7198 559470 62922207
Disease progression 32.43 16.22 54 7291 122704 63358973
Intracranial pressure increased 27.50 16.22 13 7332 5214 63476463
Diarrhoea 27.32 16.22 158 7187 715208 62766469
Drug ineffective 26.20 16.22 51 7294 1044714 62436963
Hypophagia 25.07 16.22 24 7321 31235 63450442
Plasma cell myeloma 24.06 16.22 25 7320 35880 63445797
Vascular device infection 23.38 16.22 13 7332 7299 63474378
Flatulence 21.19 16.22 23 7322 34679 63446998
Malnutrition 21.01 16.22 16 7329 15282 63466395
Sepsis 20.72 16.22 51 7294 153072 63328605
Hyperlipasaemia 19.81 16.22 6 7339 707 63480970
Constipation 19.72 16.22 64 7281 224879 63256798
Rheumatoid arthritis 19.57 16.22 3 7342 253816 63227861
Defaecation disorder 19.27 16.22 6 7339 775 63480902
Joint swelling 19.15 16.22 7 7338 327659 63154018
Hypokalaemia 19.00 16.22 39 7306 103765 63377912
White blood cell count decreased 18.47 16.22 46 7299 139058 63342619
Urinary tract infection 17.78 16.22 69 7276 264615 63217062
Weight decreased 17.66 16.22 71 7274 276727 63204950
Immune-mediated enterocolitis 16.74 16.22 7 7338 2104 63479573
Malignant neoplasm progression 16.40 16.22 32 7313 82089 63399588

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 157.14 16.11 151 7964 98945 34849871
Toxicity to various agents 128.04 16.11 192 7923 200170 34748646
Hangover 68.40 16.11 20 8095 1031 34947785
Brain oedema 51.91 16.11 35 8080 13786 34935030
Respiratory depression 51.33 16.11 37 8078 16208 34932608
Nausea 48.83 16.11 181 7934 339727 34609089
Decreased appetite 48.36 16.11 114 8001 166278 34782538
Aggression 42.93 16.11 49 8066 38915 34909901
Failure to thrive 40.21 16.11 25 8090 8576 34940240
Poisoning 38.97 16.11 28 8087 12198 34936618
Dehydration 38.76 16.11 90 8025 129879 34818937
Asphyxia 34.85 16.11 21 8094 6814 34942002
Muscle mass 31.04 16.11 8 8107 256 34948560
Vomiting 30.66 16.11 126 7989 247495 34701321
Pulmonary oedema 27.96 16.11 44 8071 47485 34901331
Seizure 26.32 16.11 68 8047 104789 34844027
Weight decreased 26.11 16.11 95 8020 176206 34772610
Dysarthria 25.94 16.11 36 8079 34746 34914070
Testicular atrophy 24.65 16.11 8 8107 584 34948232
Drug dependence 24.23 16.11 29 8086 24188 34924628
Death 23.40 16.11 165 7950 397884 34550932
Substance abuse 23.21 16.11 17 8098 7624 34941192
Myocardial fibrosis 22.58 16.11 9 8106 1188 34947628
Sleep disorder 22.44 16.11 32 8083 31656 34917160
Fatigue 21.98 16.11 154 7961 370499 34578317
Adrenergic syndrome 21.79 16.11 5 8110 97 34948719
Cardiac death 19.94 16.11 8 8107 1075 34947741
Confusional state 19.91 16.11 76 8039 144084 34804732
Plasma cell myeloma 19.50 16.11 35 8080 42002 34906814
Rebound effect 19.16 16.11 11 8104 3263 34945553
Drug screen negative 18.97 16.11 5 8110 175 34948641
Paradoxical drug reaction 18.92 16.11 11 8104 3340 34945476
Neonatal infection 18.86 16.11 6 8109 411 34948405
Withdrawal syndrome 17.82 16.11 18 8097 12437 34936379
Mucosal infection 17.73 16.11 5 8110 226 34948590
Drug screen positive 17.27 16.11 11 8104 3932 34944884
Drug withdrawal syndrome 17.03 16.11 22 8093 19812 34929004
Neuromuscular blockade 17.00 16.11 5 8110 263 34948553
Paranoia 16.47 16.11 17 8098 12051 34936765

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 159.55 14.73 163 12900 162528 79568797
Toxicity to various agents 141.97 14.73 250 12813 421290 79310035
Dehydration 85.63 14.73 149 12914 248038 79483287
Decreased appetite 77.34 14.73 172 12891 342246 79389079
Failure to thrive 77.03 14.73 38 13025 11806 79719519
Hangover 61.50 14.73 20 13043 2092 79729233
Nausea 59.71 14.73 311 12752 956885 78774440
Aggression 51.54 14.73 52 13011 50906 79680419
Respiratory depression 47.42 14.73 38 13025 27592 79703733
Brain oedema 46.05 14.73 36 13027 25227 79706098
Vomiting 43.20 14.73 219 12844 665609 79065716
Death 43 14.73 195 12868 566319 79165006
Poisoning 39.68 14.73 33 13030 25239 79706086
Asphyxia 36.05 14.73 23 13040 11697 79719628
Disease progression 35.38 14.73 87 12976 184275 79547050
Hypophagia 34.80 14.73 40 13023 45327 79685998
Plasma cell myeloma 34.36 14.73 43 13020 53216 79678109
Pulmonary oedema 33.01 14.73 55 13008 88199 79643126
Testicular atrophy 31.10 14.73 8 13055 363 79730962
Muscle mass 29.33 14.73 8 13055 456 79730869
Dysarthria 29.20 14.73 45 13018 67577 79663748
Substance abuse 28.33 14.73 19 13044 10507 79720818
Weight decreased 26.67 14.73 122 12941 355076 79376249
Behaviour disorder 26.16 14.73 15 13048 6298 79725027
Fatigue 25.58 14.73 248 12815 929479 78801846
Infective pulmonary exacerbation of cystic fibrosis 24.92 14.73 19 13044 12832 79718493
Rheumatoid arthritis 23.89 14.73 3 13060 208467 79522858
Drug ineffective 23.81 14.73 94 12969 1080819 78650506
Drug hypersensitivity 23.14 14.73 10 13053 298906 79432419
Myocardial fibrosis 22.47 14.73 9 13054 1709 79729616
Seizure 21.55 14.73 74 12989 188760 79542565
Adrenergic syndrome 21.44 14.73 5 13058 150 79731175
Malnutrition 21.00 14.73 22 13041 22480 79708845
Joint swelling 20.29 14.73 11 13052 288635 79442690
Drug dependence 20.28 14.73 29 13034 40740 79690585
Cardiac death 19.74 14.73 8 13055 1566 79729759
Mucosal infection 19.63 14.73 6 13057 513 79730812
Mental status changes 18.98 14.73 37 13026 66922 79664403
Defaecation disorder 17.85 14.73 6 13057 695 79730630
Confusional state 17.40 14.73 100 12963 317897 79413428
Diarrhoea 17.34 14.73 220 12843 880269 78851056
Febrile neutropenia 17.06 14.73 79 12984 230920 79500405
Hypersensitivity 17.01 14.73 11 13052 262228 79469097
Malignant neoplasm progression 16.13 14.73 54 13009 135936 79595389
Hypokalaemia 16.04 14.73 56 13007 143984 79587341
Accidental poisoning 16.02 14.73 7 13056 1650 79729675
Agitation 15.96 14.73 44 13019 99671 79631654
White blood cell count decreased 15.87 14.73 67 12996 188221 79543104
Intracranial pressure increased 15.47 14.73 12 13051 8310 79723015
Vascular device infection 15.26 14.73 13 13050 10263 79721062
Accidental overdose 15.24 14.73 25 13038 39556 79691769
Arthralgia 15.04 14.73 46 13017 571757 79159568
Neuromuscular blockade 14.91 14.73 5 13058 575 79730750
Paradoxical drug reaction 14.77 14.73 11 13052 7174 79724151

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A04AD10 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
FDA CS M0003267 Cannabinoids
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D063386 Cannabinoid Receptor Agonists
MeSH PA D063385 Cannabinoid Receptor Modulators
MeSH PA D002491 Central Nervous System Agents
MeSH PA D006213 Hallucinogens
MeSH PA D006728 Hormones
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018689 Sensory System Agents
FDA EPC N0000175782 Cannabinoid
CHEBI has role CHEBI:25212 metabolites
CHEBI has role CHEBI:35499 hallucinogens
CHEBI has role CHEBI:53000 epitope role
CHEBI has role CHEBI:67072 cannabinoid receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000
Anorexia from HIV indication
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Lowered convulsive threshold contraindication 19260006
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Low blood pressure contraindication 45007003
Schizophrenia contraindication 58214004 DOID:5419
Substance abuse contraindication 66214007
Epilepsy contraindication 84757009 DOID:1826
Syncope contraindication 271594007
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.15 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cannabinoid receptor 1 GPCR AGONIST Ki 8.54 CHEMBL CHEMBL
Fatty-acid amide hydrolase 1 Enzyme IC50 4.36 CHEMBL
D(3) dopamine receptor GPCR EC50 7.99 CHEMBL
Glycine receptor subunit alpha-1 Ion channel EC50 5.89 CHEMBL
Glycine receptor subunit alpha-2 Ion channel ALLOSTERIC MODULATOR EC50 6 IUPHAR
Cannabinoid receptor 2 GPCR Ki 8.48 CHEMBL
Glycine receptor subunit alpha-3 Ion channel ALLOSTERIC MODULATOR EC50 5.30 IUPHAR
N-arachidonyl glycine receptor GPCR EC50 6.02 CHEMBL
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 4.90 IUPHAR
Monoacylglycerol lipase ABHD12 Enzyme IC50 4.94 CHEMBL
G-protein coupled receptor 55 GPCR IC50 4.85 CHEMBL
Cannabinoid receptor GPCR Ki 7.39 CHEMBL
L-lactate dehydrogenase A chain Enzyme Ki 4.85 CHEMBL
Monoacylglycerol lipase ABHD6 Enzyme IC50 4.32 CHEMBL
Cannabinoid receptor 1 GPCR Ki 7.43 CHEMBL
Cannabinoid receptor 2 GPCR Ki 8.04 CHEMBL
Cannabinoid receptor 1 GPCR Ki 7.40 CHEMBL
Cannabinoid receptor GPCR Ki 7.34 CHEMBL
Transient receptor potential cation channel subfamily V member 2 Ion channel ACTIVATOR EC50 4.85 IUPHAR

External reference:

IDSource
4018511 VUID
N0000146833 NUI
D00306 KEGG_DRUG
4018511 VANDF
CHEBI:66964 CHEBI
TCI PDB_CHEM_ID
CHEMBL465 ChEMBL_ID
5547 INN_ID
DB00470 DRUGBANK_ID
7J8897W37S UNII
10402 RXNORM
138250 MMSL
1589 MMSL
4645 MMSL
d00866 MMSL
001685 NDDF
010757 NDDF
108415005 SNOMEDCT_US
386846008 SNOMEDCT_US
72024007 SNOMEDCT_US
96225007 SNOMEDCT_US
C0039663 UMLSCUI
D013759 MESH_DESCRIPTOR_UI
16078 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0527-1450 CAPSULE 2.50 mg ORAL ANDA 26 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0527-1451 CAPSULE 5 mg ORAL ANDA 26 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0527-1452 CAPSULE 10 mg ORAL ANDA 26 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 0527-4125 CAPSULE 2.50 mg ORAL ANDA 18 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 0904-6745 CAPSULE 2.50 mg ORAL ANDA 31 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 0904-6745 CAPSULE 2.50 mg ORAL ANDA 31 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 0904-6746 CAPSULE 5 mg ORAL ANDA 31 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 0904-6746 CAPSULE 5 mg ORAL ANDA 31 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7144 CAPSULE 2.50 mg ORAL NDA 29 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7144 CAPSULE 2.50 mg ORAL NDA 29 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7145 CAPSULE 5 mg ORAL NDA 29 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7145 CAPSULE 5 mg ORAL NDA 29 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-761 CAPSULE 2.50 mg ORAL ANDA 32 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-761 CAPSULE 2.50 mg ORAL ANDA 32 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-762 CAPSULE 5 mg ORAL ANDA 32 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-762 CAPSULE 5 mg ORAL ANDA 32 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-763 CAPSULE 10 mg ORAL ANDA 32 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-763 CAPSULE 10 mg ORAL ANDA 32 sections
SYNDROS HUMAN PRESCRIPTION DRUG LABEL 1 20482-335 SOLUTION 5 mg ORAL NDA 32 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 31722-960 CAPSULE 2.50 mg ORAL ANDA 19 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 31722-961 CAPSULE 5 mg ORAL ANDA 19 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 31722-962 CAPSULE 10 mg ORAL ANDA 19 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 42291-449 CAPSULE 2.50 mg ORAL ANDA 19 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 42291-450 CAPSULE 5 mg ORAL ANDA 19 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 42291-451 CAPSULE 10 mg ORAL ANDA 19 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 42858-867 CAPSULE 2.50 mg ORAL ANDA 31 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 42858-867 CAPSULE 2.50 mg ORAL ANDA 31 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 42858-868 CAPSULE 5 mg ORAL ANDA 31 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 42858-868 CAPSULE 5 mg ORAL ANDA 31 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 42858-869 CAPSULE 10 mg ORAL ANDA 31 sections